Currently viewing the tag: "NGAL"
I forbindelse med EPO’s “intention to grant” af NGAL eksklusionspatentet kan det være at det er tiden med en lille update på patentsituationen.
Hvis vi ser på eksklusionspatentet først, så må jeg indrømme at det er overraskende at Bioporto har fået det, da den ansøgning har levet et liv på kanten fra først færd af. […]
er der her lige et run-down over nogle af de finansieringsmuligheder BioPorto har – bestemt ikke udtømmende – og der må gerne (meget gerne) kommenteres/rettes – så be my Guest. det er et såkaldt “work in progress” – jeg retter gerne 🙂
Opgaven er at skaffe de 25-30 millioner kroner som BioPorto – ifølge egen […]
Efter en slumrende tilværelse som “formentlig ikke patenterbar patentansøgning” har: “Diagnostic test to exclude significant renal injury” ansøgningen (bedre kendt som “ekslusions ansøgningen”) måske alligevel vist sig at indeholde potentiale.
7. September 2012 meddeler EPO at ansøgingen ikke kan godkendes, og at Bioporto får 4 måneder til at rette henvendelse hvis de alligevel mener, at […]
‘Nyheden’ fra Bioportos egen distributørkongres har vist som som et sandt overflødighedshorn af information, så jeg vil lige komme med mine seneste tanker om den.
I min chatmonolog fra i lørdags sad jeg og regnede lidt på hvad “Dr. Andreas Peter
Head of Central Laboratory, Department of Internal Medicine, University of Tuebingen, Germany” udsagn […]
I starten af August 2012 skrev Stengaard et indlæg vedrørende traume patentet’s behandling hos de amerikanske patentmyndigheder USPTO. The recent development in Triage/Trauma NGAL-patent.
Der er nu kommet nyt materiale i den sag, i form af svar fra Bioportos patentsagfører i USPTO, Kristina Bieker-Brady.
Applicant Arguments/Remarks Made in […]
On october 12th 2012 Alere was granted a USpatent on Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
as the abstract says :
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to […]
interesting article about CKD stemming from West Nile Virus, and how measurement of NGAL levels can possibly help in detecting this. With the ONLY reliable and precise NGAL -test with supreme linearity BioPorto may jus have the ideal tool for that.
To my knowledge it is the first time NGAL is mentioned in a proposed […]
Bioporto has filed for more US patents, all related to measurement of NGAL. One thing strikes you when you look at the various applications.
Take a look for yourself – if at first you don´t see the common denominator scroll down
Exclusion patent.
The ratio patent:
The CutOff patent:
scroll […]
Today BioPorto was granted their first US patent (the ratio patent) . This is truly a milestone… Hip-Hip-Hooray… The Patent is measuring the ratio between NGAL levels in urine and plasma.
Why is this important – you might ask…
A: it is the FIRST US patent – its significance can not be overrated
B: It is […]
“When – oh when – will we see a Distribution Agreement ? ” This must have been the most prominent question on the minds of BioPorto-shareholders this year.
Looking at the debates/discussions/polls here on MI – (The Lesser Evil) it certainly has been the predominant topic (apart from OD and EPO)
One could of […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
